220 related articles for article (PubMed ID: 21850490)
41. Moutan Cortex Radicis inhibits the nigrostriatal damage in a 6-OHDA-induced Parkinson's disease model.
Choi YG; Hong YM; Kim LH; Yeo S; Lim S
Chin J Nat Med; 2018 Jul; 16(7):490-498. PubMed ID: 30080647
[TBL] [Abstract][Full Text] [Related]
42. Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Kabuto H; Yamanushi TT
Neurochem Res; 2011 Dec; 36(12):2244-9. PubMed ID: 21769642
[TBL] [Abstract][Full Text] [Related]
43. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
[TBL] [Abstract][Full Text] [Related]
44. The C-terminal domain of the heavy chain of tetanus toxin given by intramuscular injection causes neuroprotection and improves the motor behavior in rats treated with 6-hydroxydopamine.
Mendieta L; Bautista E; Sánchez A; Guevara J; Herrando-Grabulosa M; Moran J; Martínez R; Aguilera J; Limón ID
Neurosci Res; 2012 Oct; 74(2):156-67. PubMed ID: 22967672
[TBL] [Abstract][Full Text] [Related]
45. Neuroprotection by silencing iNOS expression in a 6-OHDA model of Parkinson's disease.
Li M; Dai FR; Du XP; Yang QD; Chen Y
J Mol Neurosci; 2012 Sep; 48(1):225-33. PubMed ID: 22638860
[TBL] [Abstract][Full Text] [Related]
46. Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease.
Soto-Otero R; Méndez-Alvarez E; Hermida-Ameijeiras A; López-Real AM; Labandeira-García JL
Biochem Pharmacol; 2002 Jul; 64(1):125-35. PubMed ID: 12106613
[TBL] [Abstract][Full Text] [Related]
47. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy.
Tunçel N; Sener E; Cerit C; Karasu U; Gürer F; Sahintürk V; Bayçu C; Ak D; Filiz Z
Peptides; 2005 May; 26(5):827-36. PubMed ID: 15808913
[TBL] [Abstract][Full Text] [Related]
48. Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
Yang J; Hu LF; Liu X; Zhou F; Ding JH; Hu G
Life Sci; 2006 Mar; 78(17):1940-4. PubMed ID: 16216278
[TBL] [Abstract][Full Text] [Related]
49. Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway.
Lou H; Jing X; Wei X; Shi H; Ren D; Zhang X
Neuropharmacology; 2014 Apr; 79():380-8. PubMed ID: 24333330
[TBL] [Abstract][Full Text] [Related]
50. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats.
Mishra A; Krishnamurthy S
Neurotox Res; 2019 Apr; 35(3):542-562. PubMed ID: 30610666
[TBL] [Abstract][Full Text] [Related]
51. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
52. Pretreatment with potassium channel blockers of 4-aminopyridine and tetraethylammonium attenuates behavioural symptoms of Parkinsonism induced by intrastriatal injection of 6-hydroxydopamine; the role of lipid peroxidation.
Haghdoost-Yazdi H; Piri H; Faraji A; Fraidouni N; Dargahi T; Mahmudi M; Alipour Heidari M
Neurol Res; 2016 Apr; 38(4):294-300. PubMed ID: 27098232
[TBL] [Abstract][Full Text] [Related]
53. Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Alachkar A; Brotchie JM; Jones OT
J Mol Neurosci; 2012 Jan; 46(1):145-52. PubMed ID: 21562737
[TBL] [Abstract][Full Text] [Related]
54. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Crocker SJ; Wigle N; Liston P; Thompson CS; Lee CJ; Xu D; Roy S; Nicholson DW; Park DS; MacKenzie A; Korneluk RG; Robertson GS
Eur J Neurosci; 2001 Jul; 14(2):391-400. PubMed ID: 11553289
[TBL] [Abstract][Full Text] [Related]
55. Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Nowak P; Kostrzewa RA; Skaba D; Kostrzewa RM
Neurotox Res; 2010 Apr; 17(3):299-304. PubMed ID: 19760476
[TBL] [Abstract][Full Text] [Related]
56. Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats.
Haddadi R; Mohajjel Nayebi A; Brooshghalan SE
Neurosci Lett; 2013 Oct; 555():106-11. PubMed ID: 24045063
[TBL] [Abstract][Full Text] [Related]
57. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Mo J; Zhang H; Yu LP; Sun PH; Jin GZ; Zhen X
Neurobiol Aging; 2010 Jun; 31(6):926-36. PubMed ID: 18707801
[TBL] [Abstract][Full Text] [Related]
58. Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats.
Henze C; Earl C; Sautter J; Schmidt N; Themann C; Hartmann A; Oertel WH
Brain Res; 2005 Aug; 1052(1):97-104. PubMed ID: 16005444
[TBL] [Abstract][Full Text] [Related]
59. Reduction of motor disorder in 6-OHDA-induced severe parkinsonism rats by post treatment with granulocyte-colony stimulating factor.
Liao CH; Chen SY; Kuo JS; Pang CY
Chin J Physiol; 2013 Jun; 56(3):147-54. PubMed ID: 23656216
[TBL] [Abstract][Full Text] [Related]
60. High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.
Rui G; Guangjian Z; Yong W; Jie F; Yanchao C; Xi J; Fen L
Behav Brain Res; 2013 Jan; 237():263-9. PubMed ID: 23036843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
